palmitoylethanolamide.com.au
HomeResearchTeresa 2023

In Vitro and In Vivo Safety of Hyaluronic Acid-Decorated Microparticles for Intravitreal Injection of Palmitoylethanolamide, Citicoline, or Glial-Cell-Derived Neurotrophic Factor

Teresa Silvestri, Alejandra Daruich, Fatima Domenica Elisa De Palma, Valentina Mollo, Marie Christine Naud, Danilo Aleo, Fabiola Spitaleri, Guido Kroemer, Francine Behar-Cohen, Marco Biondi, Emilie Picard, Maria Chiara Maiuri, Laura Mayol. Biomacromolecules. 2023 Aug 14;24(8):3510-3521.

Laboratory studyHumansOther animals

Design
Laboratory study
Subjects
Human ARPE-19 retinal pigment epithelial cells and an unspecified in vivo model
Dose used in the study
PLGA microparticles decorated with hyaluronic acid and loaded with palmitoylethanolamide, citicoline or GDNF, for intravitreal injection; amounts not stated
Duration
Not stated in the abstract
What was measured
Microparticle characteristics, cell viability in vitro, and in vivo safety of empty and loaded particles

What the authors reported

This safety study found:

  • Microparticles had a satisfactory safety profile on ARPE-19 cells.
  • Free GDNF reduced cell viability while sustained-release GDNF did not.
  • In vivo results confirmed the safety of both empty and loaded microparticles.
  • No efficacy was tested.

Limits of this study

A safety and formulation study in cells and an animal model; it cannot show effect in people. The abstract does not name the animal species or give doses. Funding and conflicts not stated in the abstract.

Source

PubMed 37531486 · doi:10.1021/acs.biomac.3c00276

Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.